Literature DB >> 30129449

Biosimilars for insulin: a cost-saving alternative?

Chris McCall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30129449     DOI： 10.1016/S0140-6736(18)31730-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Insulin prices, availability and affordability in 13 low-income and middle-income countries.

Authors:  Margaret Ewen; Huibert-Jan Joosse; David Beran; Richard Laing
Journal:  BMJ Glob Health       Date:  2019-06-11

2.  [Insulin: prices, availability, and affordability in public and private Peruvian pharmaciesPreço, disponibilidade e acessibilidade à insulina em farmácias públicas e privadas no Peru].

Authors:  Janeth Tenorio-Mucha; María Lazo-Porras; Liliana Hidalgo-Padilla; David Beran; Margaret Ewen
Journal:  Rev Panam Salud Publica       Date:  2019-10-31

3.  Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals.

Authors:  Iga Pawłowska; Leszek Pawłowski; Natalia Krzyżaniak; Ivan Kocić
Journal:  BioDrugs       Date:  2019-04       Impact factor: 5.807
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.